Neurogene Inc. develops genetic medicines for rare neurological diseases, with recurring updates centered on NGN-401, its investigational AAV9 gene therapy for Rett syndrome. Company news covers the EXACT™ transgene regulation technology, intracerebroventricular delivery for CNS-targeted gene therapy, clinical data from NGN-401 studies, and regulatory designations granted by U.S., European, and U.K. agencies.
Other recurring Neurogene developments include financial results, corporate presentations, scientific conference participation, board and executive appointments, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). The company also identifies NGN-101 as a conventional gene therapy development candidate for CLN5 Batten disease.
Neurogene (NGNE) reported a third-quarter 2026 net loss of $29.023 million while advancing its NGN-401 gene therapy for Rett syndrome. The loss widened from $20.953 million a year earlier; loss per share increased to $1.05 from $0.99. Cash, cash equivalents and short-term investments totaled $359.7 million at September 30, which the company expects to fund planned operations into the first quarter of 2029.
Neurogene expects Embolden registrational trial topline data in the second half of 2027 and manufacturing qualification runs to finish by year-end 2026. All 25 dosed participants will enter the primary efficacy analysis; the success threshold is 9 of 25 participants (36%). NGN-401 at the 1E15 vg dose remained generally well-tolerated across the Phase 1/2 and Embolden trials (N=35) as of November 8, 2026. Quarterly research and development and administrative expenses both increased year over year.
Neurogene (Nasdaq: NGNE) approved an inducement grant of stock options to purchase 2,010 common shares for one new employee. The Compensation Committee approved the award on November 3, 2026, under the 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The exercise price equals the stock’s closing price on the grant date. Vesting runs over four years: 25 percent on the first anniversary of the vesting commencement date, followed by 1/48 of the total award monthly over the next three years, subject to continued employment through each vesting date.
Neurogene (NGNE) management will participate in fireside chats and investor meetings at two upcoming healthcare investor conferences.
The Guggenheim 3rd Annual Healthcare Innovation Conference chat is scheduled for November 10 at 10:30 a.m. ET; the Stifel 2026 Healthcare Conference chat is scheduled for November 11 at 10:40 a.m. ET. Live webcasts and limited-time replays will be available through the company’s Investor Relations website.
Neurogene (Nasdaq: NGNE) will present new preclinical findings for its Rett syndrome gene therapy NGN-401 at the ESGCT Congress.
Full-length MeCP2 expression was detected by Day 7, the earliest assessment, in all brain and nervous system tissues evaluated and persisted through the three-month study. Phase 1/2 participants showed clinical improvements at a median of two months after treatment, with improvement continuing across follow-up through 30 months at the June 16, 2026 data cutoff.
A separate preclinical study found that two miRNA-based regulation technologies reduced transgene output regardless of cells' existing MeCP2 levels. Encore preclinical data showed broader central nervous system distribution with delivery into brain ventricles than with lumbar spinal delivery.
Neurogene (Nasdaq: NGNE) will present NGN-401 Rett syndrome gene therapy data at the ESGCT congress taking place October 27–30, 2026. The meeting will be held in Hamburg, Germany.
Presentations will cover new preclinical data on how quickly single-stranded AAV, a viral delivery vehicle, produces MECP2 gene expression, alongside early time-to-response observations from the Phase 1/2 trial. Other work evaluates approaches to regulating expression in individual cells, including Neurogene’s EXACT technology, in a preclinical Rett syndrome model. Talks and posters on October 28–29 will also address delivery into the brain’s fluid-filled spaces and provide an overview of EXACT.
Neurogene (NGNE) announced stock option inducement grants covering 8,340 common shares for five new employees under its 2025 Inducement Plan.
The Compensation Committee approved the grants on October 5, 2026, under Nasdaq Listing Rule 5635(c)(4). The exercise price equals the stock’s closing price on the grant date. Options vest over four years: 25 percent on the first anniversary of the vesting commencement date, then 1/48 of the total award monthly over the following three years, subject to continued employment through each vesting date.
Neurogene (NGNE)/b) will participate in the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15 at 1:00 p.m. ET.Company management is scheduled for a fireside chat and investor meetings. A live webcast of the fireside chat will be available through the Investor Relations section of Neurogene’s website under events, with a replay accessible there for a limited time.
Neurogene (NGNE) granted non-qualified stock options to purchase a total of 38,330 shares of common stock to two new employees on September 1, 2026. These awards were approved by the Board’s Compensation Committee under the company’s 2025 Inducement Plan and are intended as inducement grants under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing price of Neurogene’s common stock on the grant date. They vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.
Neurogene (Nasdaq: NGNE) reported second quarter 2026 results and progress on its NGN-401 Rett syndrome gene therapy. Phase 1/2 data (N=10) showed 100% of participants improved on CGI-I and gained ≥1 developmental milestone, averaging 4.7 milestones, with continued gains through 30 months and no plateau or milestone loss as of June 16, 2026.
According to Neurogene, 7 of 10 participants gained ≥2 milestones and improved across ≥2 Rett domains, with significant benefits on RSGMS and RSHFS (p<0.001). NGN-401 was generally well-tolerated at 1E15 vg in 35 participants across trials as of August 10, 2026. All 25 Embolden registrational trial participants have been dosed, with topline data expected in 2H 2027, and a PPQ manufacturing campaign initiated in July 2026 to support a planned BLA, with PPQ runs targeted for completion by year-end 2026.
The company completed an oversubscribed follow-on offering for approximately $144 million in gross proceeds. Cash, cash equivalents and short-term investments were $225.4 million at June 30, 2026, rising to a pro forma $360.2 million with July offering proceeds, which Neurogene expects to fund operations into 1Q 2029. Second quarter 2026 R&D and G&A expenses were $25.5 million and $11.2 million, respectively, and net loss was $34.5 million.
Neurogene (Nasdaq: NGNE) announced that its Board’s Compensation Committee approved non-qualified stock option inducement grants covering an aggregate of 12,555 shares of common stock for four new employees, effective August 3, 2026, under the company’s 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
According to Neurogene, the options have an exercise price equal to the closing price on the grant date. The awards vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.